A new publication involving FOXO4-DRI, an unapproved research compound, appeared on July 2, 2026. The study, titled "Acylglycerol Kinase Sensitizes Glioblastoma to Temozolomide via Limiting Mitochondrial Damage Related Cellular Senescence," was published in Molecular Carcinogenesis. The publication is indexed under PubMed ID 42391447.
This brief reports only that the publication exists and its listed title, journal, and date. No findings, results, or conclusions from the study are described here, as that data was not provided. FOXO4-DRI remains classified as an unapproved research compound and is not authorized for clinical use.
Readers interested in the study details can consult the publication directly through the linked source. For general background on FOXO4-DRI, including its research classification and status, see the compound overview.